ASBP (Aspire-Lakewood Holdings) Other Stockholders Equity: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASBP Aspire-Lakewood Holdings Inc ASBP
11 GF Score
Price $9.25
! 2 Warning Signs
View Full Analysis

What is Aspire-Lakewood Holdings Other Stockholders Equity?

Aspire-Lakewood Holdings ASBP +2.42% 11 Other Stockholders Equity is $0.00 Mil as of Jun. 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Aspire-Lakewood Holdings's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $0.00 Mil.

Aspire-Lakewood Holdings's quarterly Other Stockholders Equity declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil) and declined from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Aspire-Lakewood Holdings's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Aspire-Lakewood Holdings Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aspire-Lakewood Holdings's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspire-Lakewood Holdings Other Stockholders Equity Chart

Aspire-Lakewood Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
-0.00 -0.00 0.00 0.00

Aspire-Lakewood Holdings Quarterly Data
Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
ASBP
11GF Score
Aspire-Lakewood Holdings Inc ASBP
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspire-Lakewood Holdings Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Aspire-Lakewood Holdings (ASBP) has a Other Stockholders Equity of $0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aspire-Lakewood Holdings and its competitors.
Is Aspire-Lakewood Holdings' Other Stockholders Equity too high?
Aspire-Lakewood Holdings' current Other Stockholders Equity is $0.00 Mil. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' Other Stockholders Equity compare to PDSB and KPRX?
Aspire-Lakewood Holdings' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aspire-Lakewood Holdings and its competitors. Aspire-Lakewood Holdings's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current Other Stockholders Equity is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aspire-Lakewood Holdings Business Description

Address 23150 Fashion Drive, Suite 232, Estero, FL, USA, 33928
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score

Get the complete analysis for ASBP

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.25
Price